Clinical Trial Update: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) [Phase 3]

View source ↗

Summary

A Phase III multicenter randomized trial comparing RIT versus ASCT in relapsed/refractory follicular lymphoma; status and results are not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• ASCT
• RIT

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Relapsed Follicular Lymphoma | Phase 3 | Status: UNKNOWN